Abbvie Inc - ABBV - US00287Y1091

Informatie en analyses over uw favoriete aandeel zoals: Tesla, Apple, Microsoft, Amazon, NVIDIA, Alibaba, META, Alphabet, Tencent, Nike en Disney
Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

Drukke dagen voor overnemers, in de Healthcare sector in de USA. ;)

Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

:clap:


Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

Gebruikersavatar
quince
Ervaren poster
Ervaren poster
Berichten: 798
Lid geworden op: 23 jan 2022 19:26
Heeft bedankt: 626 maal
Is bedankt: 858 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door quince »

November 30, 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
  • Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer
  • ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer
  • ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations
  • ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignancies
  • Transaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billion
  • AbbVie to hold an investor conference call at 8:00 a.m. CT
(...)
Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

nobody
Forumveteraan
Forumveteraan
Berichten: 10323
Lid geworden op: 09 mar 2022 13:32
Heeft bedankt: 1543 maal
Is bedankt: 1929 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door nobody »

AbbVie to buy drug developer Cerevel for $8.7 billion

(Reuters) - AbbVie said on Wednesday it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competition.

It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines.

It is paying $45 per share in cash for Cerevel, which is developing drugs for Alzheimer's, Parkinson's, psychosis, epilepsy, and panic disorder. Its experimental drug emraclidine is in midstage trials as a treatment for schizophrenia that will yield data the company hopes can be used to seek regulatory approval.

The deal represents a 73% premium to Ceverel's closing share price on Dec. 1, before rumors started circulating among traders about a potential sale of the company. The stock had risen 42% since Dec. 1, when Reuters reported on Wednesday afternoon that AbbVie was nearing a deal to buy the company for $45 per share.

Revenue from Humira, once the top-selling drug in the world, is expected to fall precipitously following market entry of over half a dozen biosimilar versions of the drugs this year in the U.S. It already faced competition in Europe.

Humira sales, which topped out above $21 billion in 2022, are expected to be below $9 billion next year.

Meanwhile, sales of AbbVie's blockbuster leukemia drug Imbruvica dropped 20% in the third quarter due to competition from BeiGene's Brukinsa and AstraZeneca's Calquence.

Imbruvica is also one of the 10 drugs that will be subject to the first-ever price negotiations by U.S. Medicare health plans, with new prices expected to come into effect in 2026.

Cambridge, Massachusetts-based Cerevel was started in 2018 when Pfizer carved out its division developing drugs for the central nervous system into a standalone company backed by a $350 million investment from Bain.

Cerevel was listed on the New York stock market in 2020. Bain and Pfizer hold stakes of about 36% and 15%, respectively.

Cerevel shares were up 15.5%, while AbbVie shares were flat in extended trading.

(Reporting by Ananya Mariam Rajesh and Christy Santhosh in Bengaluru, Michael Erman in New Jersey and Greg Roumeliotis in New York; Editing by Shinjini Ganguli and Bill Berkrot)

https://www.marketscreener.com/quote/st ... -45516373/
Gebruikersavatar
joni
Forumveteraan
Forumveteraan
Berichten: 2412
Lid geworden op: 06 jan 2022 17:06
Heeft bedankt: 609 maal
Is bedankt: 1764 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door joni »

nobody
Forumveteraan
Forumveteraan
Berichten: 10323
Lid geworden op: 09 mar 2022 13:32
Heeft bedankt: 1543 maal
Is bedankt: 1929 maal

Re: Abbvie Inc - ABBV - US00287Y1091

Bericht door nobody »

Is Abbvie Stock a Buy Now!? | Abbvie (ABBV) Stock Analysis! |

Dividendology

In this video, we analyze Abbvie stock.


Plaats reactie

Maak een account aan of log in om deel te nemen aan het forum

Je moet lid zijn om een reactie te kunnen plaatsen

Maak een account aan

Geen lid? Registreer om lid te worden van onze community
Leden kunnen bijlages zien, eigen onderwerpen starten en abonneren op onderwerpen
Het is gratis en duurt maar een minuut

Registreer

Log in